• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    33307509.pdf
    Size:
    862.5Kb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Fischer, Stefanie C
    Clements, S.
    McWilliam, Alan
    Green, Andrew
    Descamps, Tine
    Oing, Christoph
    Gillessen, Silke
    Affiliation
    Manchester Cancer Research Centre, Division of Cancer Sciences, University of Manchester, 555 Wilmslow Road, Manchester M204GJ, United Kingdom
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Introduction: Loss of skeletal muscle (SM) and gain of subcutaneous fat (SCF) are known side-effects of androgen-deprivation in treatment of prostate cancer. Scarce data is available concerning the effects of abiraterone/pred (ABI) on body composition and no published data regarding enzalutamide (ENZA). Our objective was to analyse the effects of ENZA on SM/SCF and to compare the results with ABI in patients with metastatic castration-resistant prostate-cancer (mCRPC). Patients and methods: 54 patients starting ABI (n = 17) or ENZA (n = 37) at a single-centre between 2012 and 2018 were retrospectively identified. SM and SCF were assessed using CT-scans at baseline and after a median of 10.8 months on treatment. A deep learning image-segmentation software was used to quantify SM and SCF. In a subgroup of patients receiving ENZA within a trial, we investigated change of SM using serial timepoints. Results: Median time of treatment with ABI/ENZA was 14.6 months. A significant loss of SM compared to baseline was observed for ENZA (mean loss 5.2%, p<0.0001) and ABI (mean loss 3.0%, p = 0.02). SCF was not significantly altered. The effects of both drugs did not differ significantly. Loss of SM occurred early on during treatment with ENZA. Conclusion: Treatment with ENZA seems to lead to a loss of SM which is comparable to that of ABI. Further evaluation in larger patient-cohorts is warranted. In routine care, counselling of patients about side effects of ABI/ENZA should include discussions about SM loss.
    Citation
    Fischer S, Clements S, McWilliam A, Green A, Descamps T, Oing C, et al. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer. Cancer Treat Res Commun. 2020;25:100256.
    Journal
    Cancer Treatment and Research Communications
    URI
    http://hdl.handle.net/10541/623619
    DOI
    10.1016/j.ctarc.2020.100256
    PubMed ID
    33307509
    Additional Links
    https://dx.doi.org/10.1016/j.ctarc.2020.100256
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.ctarc.2020.100256
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
    • Authors: Szarvas T, Csizmarik A, Váradi M, Fazekas T, Hüttl A, Nyirády P, Hadaschik B, Grünwald V, Tschirdewahn S, Shariat SF, Sevcenco S, Maj-Hes A, Kramer G
    • Issue date: 2021 May
    • Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
    • Authors: Moses M, Niu A, Lilly MB, Hahn AW, Nussenzveig R, Ledet E, Manogue C, Cotogno P, Lewis B, Layton J, Agarwal N, Sartor O, Barata PC
    • Issue date: 2020
    • Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
    • Authors: Emamekhoo H, Barata PC, Edwin NC, Woo KM, Grivas P, Garcia JA
    • Issue date: 2018 Dec
    • Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
    • Authors: Xiong X, Qiu S, Yi X, Xu H, Lei H, Liao D, Bai S, Peng G, Wei Q, Ai J, Yang L
    • Issue date: 2022 Jan
    • Enzalutamide versus abiraterone acetate in the development of new-onset or worsening type 2 diabetes mellitus in patients with metastatic castration-resistant prostate cancer: EVADE study.
    • Authors: Bahl A, Sodatonou H, Snjider R, Chilelli A, Pranzo A, Martins K, Merseburger A, Rozario N, Crawley D
    • Issue date: 2024 Oct 18
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.